COST-EFFECTIVENESS OF POST-AUTOTRANSPLANT LENALIDOMIDE IN PERSONS WITH MULTIPLE MYELOMA.

Considerable data indicate posttransplant lenalidomide prolongs progression-free survival and probably survival after an autotransplant for plasma cell myeloma (PCM).  However, optimal therapy duration is unknown, controversial and differs in the EU and US.  We compared outcomes and cost-effectivene...

Full description

Saved in:
Bibliographic Details
Main Authors: Monia Marchetti, Robert Peter Gale, Giovanni Barosi
Format: Article
Language:English
Published: PAGEPress Publications 2021-04-01
Series:Mediterranean Journal of Hematology and Infectious Diseases
Subjects:
Online Access:https://www.mjhid.org/index.php/mjhid/article/view/4555
Tags: Add Tag
No Tags, Be the first to tag this record!